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Fibrinogen-like protein 2 (Fgl2) is critical for immune regulation in the inflammatory state. 
Elevated Fgl2 levels are observed in patients with inflammatory bowel disease (IBD), but 
little is known about its functional significance. In this study, we sought to investigate 
the role of Fgl2 in the development of intestinal inflammation and colitis-associated 
colorectal cancer (CAC). Here, we report that Fgl2 deficiency increased susceptibility to 
dextran sodium sulfate-induced colitis and CAC in a mouse model. During colitis devel-
opment, the expression of the membrane-bound and secreted forms of Fgl2 (mFgl2 and 
sFgl2, respectively) in the colon were increased and predominantly expressed by colonic 
macrophages. In addition, using bone marrow chimeric mice, we determined that Fgl2 
function in colitis is strictly related to its expression in the hematopoietic cells. Loss of 
Fgl2 induced the polarization of M1, but suppressed that of M2 both in vivo and in vitro, 
independent of intestinal inflammation. Thus, Fgl2 suppresses intestinal inflammation 
and CAC development through its role in macrophage polarization and may serve as a 
therapeutic target in inflammatory diseases, including IBD.
Keywords: fibrinogen-like protein 2, colitis, colitis-associated colorectal cancer, immune regulation, intestinal 
inflammation, macrophage polarization
inTrODUcTiOn
The maintenance of intestinal homeostasis requires a balance of immune tolerance and effector 
functions. Disruption of this homeostasis results in pathologies such as inflammatory bowel disease 
(IBD), of which there are two major clinical forms: ulcerative colitis and Crohn’s disease. There are 
no effective cures for IBD (1, 2). Importantly, long-term intestinal inflammation is a key risk factor 
for colitis-associated colorectal cancer (CAC) (3). IBD is characterized by abnormalities in intestinal 
immunity, specifically, the pro-inflammatory response in the gut (4, 5). Thus, further understand-
ing of the immunopathogenesis of intestinal inflammation can lead to the development of novel 
therapies for IBD.
During IBD, immune cells, including dendritic cells (DCs), neutrophils, and effector T  cells, 
activate and trigger inflammation by secreting pro-inflammatory cytokines. On the other hand, 
regulatory T cells (Tregs) suppress the mucosal immune response, although their inhibitory capacity 
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is insufficient to control IBD progression. In particular, colonic 
macrophages can both promote or inhibit IBD pathogenesis 
depending on their M1- or M2-polarized phenotype. The clas-
sically activated M1 type promotes colitis primarily by secreting 
pro-inflammatory cytokines, such as interleukin (IL)-6, -1β, and 
interferon (IFN)-γ, leading to tissue damage. In contrast, the 
alternatively activated M2 type contributes to the resolution of 
colitis via upregulation of arginase (Arg)-1, mannose receptor 
(MR), Ym1, IL-10, and Fizz1, which promote tissue repair (6–8). 
Transferring Tregs or M2 macrophages or inducing M2 polari-
zation has been shown to suppress experimental colitis (9, 10). 
Thus, activating an anti-inflammatory response in the intestine is 
an attractive strategy for restoring intestinal homeostasis.
Fibrinogen-like protein 2 (Fgl2) is a member of the fibrinogen 
superfamily that has well-known roles in the pathogenesis of 
inflammatory disorders and has multiple functions in immune 
regulation (11–13). Fgl2 has been shown to inhibit the matura-
tion of bone marrow (BM)-derived DCs and the proliferation of 
effector T  cells, promote macrophage activation, and maintain 
the immunosuppressive activity of Tregs. It also induces the 
apoptosis of B cells and macrophages (14–17). We speculated that 
the immunomodulatory activity of Fgl2 plays an important role 
in the pathogenesis of IBD. Interestingly, a clinical study reported 
that Fgl2 expression was increased in patients with active IBD 
(18). However, a comprehensive analysis of Fgl2 function in IBD 
pathogenesis is still lacking.
To address this issue, we investigated the contribution of Fgl2 
to IBD development by evaluating its expression in the inflamed 
intestine and examining the effects of Fgl2 deficiency on dextran 
sodium sulfate (DSS)-induced colitis in mice. We found that Fgl2 
is mainly expressed in colonic macrophages in colitis and sup-
presses DSS-induced colitis and subsequent CAC development. 
In addition, we demonstrate that Fgl2 regulates macrophage 
polarization and function, which is associated with the protective 
effect of Fgl2 in intestinal inflammation.
MaTerials anD MeThODs
Mice
Fibrinogen-like protein 2 knockout mice (hereafter referred 
to as Fgl2−/−) were kindly provided by Dr. Steve Smiley (The 
Trudeau Institute, NY, USA) and maintained on C57BL/6 genetic 
background. Their age-matched and sex-matched homozygous 
wild-type littermates were used as controls. C57BL/6 mice were 
obtained from the Animal Institute of the Academy of Medical 
Science (Beijing, China). All mice were kept in laminar flow 
cabinets under specific pathogen-free conditions at the Animal 
Center of the Third Military Medical University. The animal study 
protocols were approved by the Third Military Medical University 
Institutional Animal Care and Use Committee.
induction and evaluation of acute colitis 
and cac
Mice (male or female, 8–10 weeks old) were administered drinking 
water containing 2.5% DSS (MW 36–50 kDa; MP-0216011050; 
MP Biomedicals, Solon, OH, USA) for 5 or 6 days, followed by 
regular water up to 9  days. Body weight, rectal bleeding, and 
stool consistency were monitored daily. A clinical score was 
assigned based on changes in weight loss, stool consistency, and 
rectal bleeding (19). Colon tissue samples were fixed in 4% (v/v) 
paraformaldehyde, embedded in paraffin, and cut into 4-µm sec-
tions that were stained with hematoxylin and eosin. Histological 
scoring was performed to quantify epithelial damage and inflam-
matory cell infiltration (20). The severity of colitis was assessed 
by a pathologist blinded to the treatment groups. To induce CAC, 
8- to 10-week-old female mice were intraperitoneally injected 
with 10 mg/kg azoxymethane (AOM) on day 0. After 7 days, the 
mice were treated with 1.8% DSS for 5 days, followed by regular 
drinking water for 16 days. Body weight was monitored daily. The 
mice were sacrificed after three cycles of DSS administration, and 
tumor number and size (length × width) were determined.
Western Blot analysis
Mouse colonic tissue was harvested at predetermined time points 
and proteins were extracted with radioimmunoprecipitation assay 
buffer composed of 1% Triton X-100, 0.5% Na-deoxycholate, 
0.1% sodium dodecyl sulfate, 20  mmol/l Tris–HCl (pH 7.4), 
and 1% phenylmethylsulfonyl fluoride (Beyotime Institute of 
Biotechnology, Shanghai, China). Equal amounts of protein sam-
ple were resolved on a 12% sodium dodecyl sulfate-polyacrylamide 
gel and transferred to a polyvinylidene difluoride membrane. 
After blocking with 5% non-fat milk, the membrane was probed 
with primary and secondary antibodies, and immunoreactivity 
was detected by enhanced chemiluminescence (Pierce, Rockford, 
IL, USA). Anti-mouse Fgl2 antibody (clone 6D9, 1:1,000 dilution; 
Abnova, Taiwan) and anti-mouse β-actin (clone AC-15, 1:2,000 
dilution; Sigma-Aldrich, St. Louis, MO, USA) were the primary 
antibodies. Goat anti-mouse IgG (1:5,000 dilution; Beyotime 
Institute of Biotechnology) was used as a secondary antibody. The 
gray values of the western blotting bands were procured using 
ImageJ software.
immunofluorescence analysis and 
confocal Microscopy
Frozen sections of mouse colonic tissue were fixed with ice-cold 
acetone for 10  min at −20°C. After washing with phosphate-
buffered saline (PBS), the sections were incubated with blocking 
solution (5% bovine serum albumin in PBS) for 30 min at 37°C 
and then incubated overnight at 4°C with the following antibodies: 
mouse anti-mouse Fgl2 (clone 6D9, 1:100 dilution; Abnova); and 
rat anti-mouse F4/80 (clone CI:A3-1, 1:100 dilution), Armenian 
hamster anti-mouse cluster of differentiation (CD)11c (clone 
N481, 1:100 dilution), and rabbit polyclonal anti-mouse CD31 
(1:100) (all from Abcam, Cambridge, MA, USA). After washing 
four times with PBS, the sections were incubated for 30 min at 
room temperature with the following secondary antibodies: 
Cy3-labeled goat anti-mouse IgG (1:200 dilution), Alexa Fluor 
488-labeled goat anti-rabbit IgG (1:200 dilution), or Alexa Fluor 
488-labeled goat anti-rat IgG (1:200 dilution) (all from Beyotime 
Institute of Biotechnology); or Alexa Fluor 488-labeled goat 
anti-Armenian hamster antibody (1:100 dilution; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). After counterstaining 
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with 4′,6-diamidino-2-phenylindole dihydrochloride (Beyotime 
Institute of Biotechnology), the sections were observed under a 
confocal microscope (TCS SP5 X; Leica, Wetzlar, Germany).
generation of BM chimeric Mice
Bone marrow cells were flushed from the tibia and femur of WT 
and Fgl2−/− mice (6–8 weeks old), and erythrocytes were removed 
using RBC Lysis Buffer (Biolegend, San Diego, CA, USA). 
Recipient mice (6–8  weeks old) were irradiated at 1,100  rad, 
and BM  cells resuspended in 0.1  ml of 0.9% sodium chloride 
were intravenously injected via the retro-orbital plexus (5 × 106 
cells/mouse). Chimeric mice were administered antibiotic water 
(800 mg/ml gentamycin) for 1 week after BM transplantation and 
housed for 8 weeks before induction of colitis by DSS treatment. 
To confirm BM reconstitution, CD45+ allelic variants of blood 
leukocytes from chimeric mice were detected by flow cytometry 
using antibody against CD45.1 (clone A20, 1:200) or CD45.2 
(clone 140, 1:200) (both from Biolegend). Cells were sorted 
on a Canto II cytometer (BD Biosciences, Franklin Lakes, NJ, 
USA), and data were analyzed with FlowJo-X software (Tree Star, 
Ashland, OR, USA).
isolation of colonic lamina Propria (clP) 
cells by Flow cytometry
Mice were sacrificed on day 6 or 9 after DSS administration. 
The colon was cut longitudinally, washed in ice-cold PBS, and 
cut into pieces that were incubated in pre-digestion solution 
composed of Hank’s Balanced Salt Solution containing 5% fetal 
bovine serum (FBS; Gibco, Grand Island, NY, USA), 5  mM 
EDTA, and 1 mM dithiothreitol for 30 min at 37°C. Enzymatic 
digestion was performed in Iscove’s Modified Dulbecco’s Medium 
(Hyclone, Logan, UT, USA) supplemented with 5% FBS, 1 mg/
ml collagenase D (Roche Diagnostics, Indianapolis, IN, USA), 
and 0.5 mg/ml DNase I (Roche Diagnostics) for 1 h at 37°C with 
gentle shaking. The cell suspension was passed through a 100-µm 
nylon mesh and centrifuged. cLP cells were enriched on a 40/80 
Percoll gradient (Sigma-Aldrich) (21). To analyze the compo-
nents and phenotype of inflammatory cells in the colon, cLP cells 
were incubated with anti-CD16/-CD32 blocking antibody (clone 
93) and then labeled with anti-CD11b (clone M1/70), anti-F4/80 
(clone BM8), anti-CD206 (clone C068C2), anti-Dectin-1 (clone 
RH1), anti-CD11c (clone N418), anti-major histocompatibility 
complex (MHC) II (I-A/I-E, clone M5/114.15.2), and anti-Gr-1 
(clone RB6-8C5) antibodies (all from Biolegend). Antibodies 
were used at 1:100 dilution. The cells were sorted on a Canto II 
cytometer, and data were analyzed with FlowJo-X software.
Peritoneal Macrophage (PeM) isolation 
and stimulation
WT and Fgl2−/− mice (8–10 weeks old) were sacrificed and PEMs 
were isolated by flushing the peritoneal cavity with PBS. Cells 
were seeded in 12-well dishes in Roswell Park Memorial Institute 
medium supplemented with 10% FBS and 1% penicillin–strepto-
mycin (Hyclone). Non-adherent cells were removed by extensive 
washing with PBS and adherent macrophages were treated with 
100 ng/ml lipopolysaccharide (LPS; Sigma-Aldrich) or 20 ng/ml 
mouse recombinant IL-4 (PeproTech, Rocky Hill, NJ, USA) for 
further analysis.
cytokine enzyme-linked immunosorbent 
assay (elisa)
Proteins were extracted from the colon of colitic mice. Samples 
were weighed and homogenized with PBS containing 1% phenyl-
methylsulfonyl fluoride. Tumor necrosis factor (TNF)-α, IL-1β, 
-6, -17A, -10, -4, -17F, -21, -22, transforming growth factor 
(TGF)-β, and IFN-γ levels were quantified by ELISA using a 
kit (MLBIO, Shanghai, China) according to the manufacturer’s 
instructions. For in vitro stimulation of macrophage assay, PEMs 
were isolated, and the adherent macrophages were stimulated 
with LPS (100 ng/ml) or mouse recombinant IL-4 (20 ng/ml). The 
culture supernatant was collected 48 h later, and IL-1β and -10 
levels in the culture medium were detected by ELISA (MLBIO).
rna isolation and Quantitative reverse-
Transcription Pcr
Peritoneal macrophages were isolated and adherent macrophages 
were stimulated with LPS (100  ng/ml) or mouse recombinant 
IL-4 (20  ng/ml) for 12  h, and total RNA was extracted from 
inflamed colonic macrophages of WT and Fgl2−/− mice using 
TRIzol reagent (Takara Bio, Otsu, Japan) or the Micro Total RNA 
Isolation kit (Invitrogen, Carlsbad, CA, USA). The RNA was 
reverse-transcribed with Reverse Transcription Reagent (Takara 
Bio) according to the manufacturer’s instructions. Gene expres-
sion was evaluated by qPCR using a SYBR Green Premix Ex Taq 
kit (Takara Bio). The primer sequences are shown in Table S1 in 
Supplementary Material.
statistics
Quantitative data are expressed as the mean ± SEM. Data were 
analyzed using GraphPad Prism version 7 (GraphPad Software, 
San Diego, CA, USA). Differences between groups were evaluated 
with either an unpaired two-tailed Student’s t-test or analysis of 
variance with Bonferroni correction. A P-value <0.05 was consid-
ered statistically significant. All experiments were independently 
repeated at least three times.
resUlTs
identification of Fgl2 expression in Dss-
induced colitis
Given the potential importance of Fgl2 in the pathogenesis of IBD, 
we first investigated the expression pattern of Fgl2 in the colon 
under steady state and under inflammatory condition induced 
by DSS, a widely used chemical irritant that induces intestinal 
inflammation with clinical and histological features of human 
IBD (22). Fgl2 exists in a membrane-bound and a secreted form 
(mFgl2 and sFgl2, respectively) (11). We found that the expression 
of both forms was increased by DSS treatment (Figures 1A,B). We 
also noted a gradual upregulation of sFgl2 expression along with 
colitis progression (Figure 1B; Figures S1A,B in Supplementary 
Material). sFgl2 is mainly secreted by T  cells, specifically, acti-
vated Tregs (23); however, whether other types of cells secrete 
FigUre 1 | Identification of fibrinogen-like protein 2 (Fgl2)-expressing cells in dextran sodium sulfate (DSS)-induced colitis. (a,B) Colitis was induced in C57BL/6 
mice. At the indicated time points, mice were sacrificed, and colon tissue samples were obtained and analyzed for Fgl2 expression by western blotting (a) and 
enzyme-linked immunosorbent assay (ELISA) (B). (c) CD45− EpCAM+, CD4+ CD25high, CD11b+ F4/80+, CD11b+ CD11c+, and CD11b+ Gr-1+ cells were sorted from 
colon tissue samples by flow cytometry on day 7, and sFgl2 expression was determined by ELISA. (D–F) Representative immunofluorescence micrographs of 
colonic mucosa from colitic mice showing F4/80+ [(D), green], CD11c+ [(e), green], CD31+ [(F), green], and mFgl2+ [panels (D–F), red] cells. Colocalization of mFgl2 
with the macrophage or dendritic cell marker is shown in the merged images (n = 4–6 mice). Data are expressed as the mean ± SEM and are representative of 
three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not significant (as determined by one-way analysis of variance followed by Bonferroni 
correction).
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sFgl2 under colitis condition remains unclear. To address this, 
we sorted colonic epithelial cells (CD45− EpCAM+), Tregs (CD4+ 
CD25high), macrophages (CD11b+ F4/80+), DCs (CD11b+ F4/80− 
CD11c+), and neutrophils (CD11bhigh Gr-1high) on day 7 after DSS 
induction (Figure S1C in Supplementary Material) and analyzed 
sFgl2 production by ELISA. sFgl2 was detected in Tregs and DCs 
but not in epithelial cells or neutrophils. Notably, we found that 
macrophages—a dominant immune cell type in cLP that are 
important in IBD pathogenesis—expressed high levels of sFgl2 
(Figure 1C). mFgl2 is expressed by several cell types, including 
macrophages, DCs, and endothelial cells (10, 16, 17). To readily 
visualize the cells expressing Fgl2 upon DSS exposure, we carried 
out a colocalization analysis by confocal microscopy and found 
that macrophages (F4/80+ cells) (Figure  1D) and a fraction of 
DCs (CD11c+ cells) (Figure 1E), but not endothelial cells (CD31+ 
cells), expressed mFgl2 (Figure 1F). Together, these data suggest 
that Fgl2 is induced in the inflamed colon and that it is mostly 
expressed by various immune cells types, specially, macrophages, 
in DSS-induced colitis.
Fgl2 Deficiency aggravates Dss-induced 
colitis
To assess the significance of Fgl2 expression in colitis, we chal-
lenged Fgl2−/− and their WT littermates (controls) with DSS 
and then monitored their susceptibility to colitis. Upon DSS 
administration, Fgl2−/− mice exhibited greater weight loss than 
their WT counterparts (Figure  2A). Fgl2−/− mice also showed 
more severe colitis symptoms, including abundant diarrhea and 
rectal bleeding, resulting in higher clinical scores (Figure  2B). 
Colon length was measured to determine the extent of colonic 
injury and we found distinctly shorter colons in the Fgl2−/− mice 
than in the control mice (Figure  2C). Consistent with these 
observations, pathological changes in the colon were more severe 
in Fgl2−/− mice, as evidenced by larger areas of epithelial destruc-
tion, increased submucosal edema, and greater inflammatory cell 
infiltration relative to WT mice, in which tissue architecture was 
partly preserved and inflammation was limited. Consequently, 
Fgl2−/− mice had higher histological scores than their WT lit-
termates (Figure 2D). Thus, loss of Fgl2 exacerbates the clinical 
and histological features of DSS-induced colitis.
Aberrant cytokine production is closely linked to intestinal 
inflammation and the clinical symptoms of IBD (4). Therefore, 
we investigated whether loss of Fgl2 affects cytokine profiles 
after DSS treatment by measuring cytokine levels in colonic 
tissue on day 9 of DSS induction. Fgl2 deficiency was associated 
with a marked increase in the levels of the pro-inflammatory 
cytokines, including TNF-α, IL-1β, IL-17A, and IFN-γ, whereas 
the levels of IL-6, IL-17F, IL-21, and IL-22 remained unaffected. 
Conversely, the production of the regulatory cytokine IL-10 
FigUre 2 | Loss of fibrinogen-like protein 2 (Fgl2) aggravates dextran sodium sulfate (DSS)-induced colitis. Fgl2−/− mice and WT littermates were administered 
2.5% DSS in drinking water for 6 days, followed by normal drinking water for 3 days. (a) Change in weight over time is expressed as the percentage of the initial 
body weight (n = 8 for WT, n = 6 for Fgl2−/−). (B) Clinical score (n = 8 for WT, n = 6 for Fgl2−/−). (c) Colon length (n = 8 for WT, n = 6 for Fgl2−/−). (D) Representative 
hematoxylin and eosin-stained images of colon tissue samples from indicated groups of mice and corresponding histological score on day 9 of DSS induction (n = 8 
for WT, n = 6 for Fgl2−/−). (e) On day 9, pro-inflammatory and regulatory cytokine production in the colonic mucosa was evaluated by enzyme-linked immunosorbent 
assay (n = 6 per group). Data are representative of three independent experiments. Quantitative data are shown as the mean ± SEM. The statistical significance of 
differences was determined by two-way analysis of variance with Bonferroni correction (a,B) and unpaired two-tailed Student’s t-test (c–e). *P < 0.05, **P < 0.01, 
***P < 0.001, n.s., not significant.
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was decreased in Fgl2−/− as compared with WT mice upon 
DSS induction, while IL-4 and TGF-β production were largely 
unaltered (Figure  2E; Figure S2 in Supplementary Material). 
Thus, Fgl2 deficiency also promotes the inflammatory response 
in DSS-induced colitis.
Taken together, these results demonstrate that Fgl2 is critical 
for suppressing DSS-induced colitis.
hematopoietic cell-Derived Fgl2 is 
involved in limiting intestinal 
inflammation
The above results indicated that the development of colitis 
is limited by Fgl2, which is expressed predominantly, if not 
exclusively, by colonic immune cell types from the hematopoi-
etic compartment in colitis. Thus, we next aimed to ascertain 
whether hematopoietic cell-derived Fgl2 exerts protective effect 
against DSS-induced colitis. To this end, we generated two types 
of BM chimeric mice: one group consisted of lethally irradiated 
WT (CD45.1) mice engrafted with BM cells isolated from WT 
(CD45.2) littermates, yielding WT→WT BM chimeras; and the 
other group consisted of lethally irradiated WT (CD45.1) mice 
engrafted with BM  cells isolated from their Fgl2−/− littermates 
(CD45.2), yielding Fgl2−/−→WT BM chimeras, to knockout 
Fgl2 exclusively in all hematopoietic cells (Figure  3A; Figure 
S3A in Supplementary Material). As expected, 8  weeks after 
BM injection, mice harboring Fgl2−/− BM cells expressed much 
lower levels of both mFgl2 and sFgl2 than those that received WT 
FigUre 3 | Fibrinogen-like protein 2 (Fgl2) produced by hematopoietic cells regulates intestinal inflammation. (a) Bone marrow (BM) recipient mice were irradiated as 
indicated in Section “Materials and Methods,” and chimeric mice were generated by caudal vein injection of WT or Fgl2−/− mouse-derived BM cells. (B–F) After 
8 weeks, mice were subjected to dextran sodium sulfate (DSS)-induced colitis and weight loss (B), clinical score (c), and colon length (D) were evaluated. 
Representative images and quantification (e) of histological analyses are shown (n = 10 for WT→WT; n = 9 for Fgl2−/−→WT). (F) On day 9 of DSS induction, colonic 
mucosal production of pro-inflammatory and regulatory cytokines was evaluated by enzyme-linked immunosorbent assay (n = 8 for WT→WT; n = 7 for Fgl2−/−→WT). 
Data are expressed as the mean ± SEM and were replicated in two independent experiments. The statistical significance of differences was determined by two-way 
analysis of variance with Bonferroni correction (B,c) and unpaired two-tailed Student’s t-test (D–F). *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not significant.
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BM cells (Figures S3B,C in Supplementary Material). The mice 
were then subjected to DSS treatment. Significantly, Fgl2−/−→WT 
BM chimeric mice developed more severe colitis, with a pheno-
type similar to that of Fgl2−/− mice (Figure 2), as evidenced by 
weight loss (Figure 3B), clinic scores (Figure 3C), colon shorten-
ing (Figure 3D), histopathological alterations (Figure 3E), and 
inflammatory cytokine levels in colonic tissues (Figure  3F). 
These results demonstrate that Fgl2 expression by hematopoietic 
cells is essential for controlling intestinal inflammation.
loss of Fgl2 Facilitates M1 Polarization, 
Whereas it suppresses M2 Polarization
Next, we sought to further investigate the mechanism by which 
Fgl2 interferes with the progression of experimentally induced 
colitis. Given the crucial role of innate immune cells in both the 
onset and resolution of inflammation in DSS-induced colitis (10, 
24, 25) and the regulatory functions of Fgl2 in various immune 
cells, we examined whether and how loss of Fgl2 impacts colonic 
innate immune cell infiltration. On day 6 of DSS induction, there 
were no differences in the percentages of colonic macrophages, 
neutrophils, and DCs between WT and Fgl2−/− mice (Figure 4A; 
Figure S4A in Supplementary Material). Because activated mac-
rophages can be polarized into M1 or M2 subtypes and modulating 
M1/M2 polarization can affect colitis severity (10), we wondered 
if macrophage polarization is perturbed in the absence of Fgl2. 
On day 6, the percentage of MHC-II-positive M1 macrophages 
in the colon was increased in Fgl2−/− mice as compared with 
WT mice (Figure 4A), indicating that Fgl2 ablation leads to an 
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FigUre 4 | continued
FigUre 4 | Fibrinogen-like protein 2 (Fgl2) is required for regulation of M1/M2 polarization in colitis. (a,B) On day 6 (n = 5 per group) (a) and day 9 (n = 6 for WT; 
n = 6–7 for Fgl2−/−) (B) of 2.5% dextran sodium sulfate (DSS) induction, the percentage of macrophages (CD11b+ F4/80+), M1 macrophages (MHCII+), and M2 
macrophages (CD206+ or Dectin-1+) in colonic lamina propria (cLP) isolated from colitic WT and Fgl2−/− mice was detected by flow cytometry. Numbers adjacent to 
the outlined areas indicate the percentages of the gated population in each group. (c) Macrophages in the cLP were isolated from WT and Fgl2−/− mice on day 9 
after DSS colitis induction. Expression of M1- and M2-associated genes was examined by real-time PCR (n = 6 per group). Data represent the mean ± SEM and 
are representative of three independent experiments. *P < 0.05, **P < 0.01, n.s., not significant (as determined by unpaired two-tailed Student’s t-test).
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accumulation of pro-inflammatory M1 macrophages in the coli-
tic colon. This can explain the greater sensitivity of Fgl2−/− mice 
to DSS-induced colitis. In contrast, Fgl2 deficiency only slightly 
decreased the percentage of colonic CD206 or Dectin-1-positive 
M2 macrophages, although the difference was not statistically sig-
nificant (Figure 4A). Notably, at a later stage in colitis progression 
(day 9), the changes became more evident: loss of Fgl2 not only 
increased the proportion of M1 macrophages but also reduced the 
size of M2 populations (Figure 4B), suggesting that Fgl2 ablation 
promotes M1 polarization, whereas suppresses M2 polarization 
in DSS-induced colitis. On the other hand, the percentages of 
colonic neutrophils and DCs were unaffected by Fgl2 depletion 
until day 9 (Figure S4B in Supplementary Material).
M1 and M2 macrophages secrete distinct sets of cytokines (26). 
To clarify the role of Fgl2 in macrophage polarization, we sorted 
macrophages from the inflamed colon and analyzed cytokine 
production. As expected, Fgl2-deficient colonic macrophages 
isolated from DSS-treated mice produced higher levels of the M1 
effector molecule IL-1β, but lower levels of the M2 polarization 
markers MR, Arg-1, and Fizz1 (Figure 4C) in DSS colitis than 
macrophages from DSS-treated WT mice.
These data indicate that in DSS-induced colitis, Fgl2 deficiency 
facilitates macrophage polarization towards pro-inflammatory 
M1 type, while it hinders beneficial M2 polarization, which 
likely, at least in part, amplifies the release of pro-inflammatory 
cytokines at mucosal sites and increases susceptibility to 
colitis.
It is currently unclear whether Fgl2 regulates macrophage 
polarization in a cell-intrinsic manner. To evaluate this, PEMs 
isolated from WT and Fgl2−/− mice were treated with LPS and 
recombinant mouse IL-4 to induce M1 and M2 polarization, 
respectively. Upon LPS stimulation, PEMs from Fgl2−/− mice 
secreted higher levels of IL-1β and -6 and nitric oxide synthase 
2, indicating preferential differentiation into M1 macrophages 
(Figure S5A in Supplementary Material). In contrast, Fgl2-
deficient PEMs showed reduced capacity for differentiation into 
M2 cells upon IL-4 stimulation, as determined by decreased 
expression of Arg1, MR, YM1, and IL-10 (Figure S5B in 
Supplementary Material). These results indicate that Fgl2 defi-
ciency directly promotes the M1 phenotype, while suppressing 
the M2 phenotype, independent of intestinal inflammation.
Fgl2 Deficiency leads to the Development 
of cac
Colitis severity is known to influence the development of CAC 
(27). The observation that depletion of Fgl2 leads to exacerbated 
colitis prompted us to investigate whether and how Fgl2 deficiency 
affects the development of CAC. To this end, we induced CAC in 
WT and Fgl2−/− mice with the AOM/DSS protocol (Figure 5A). 
In accordance with our observations in the colitis model, during 
each cycle of DSS challenge, Fgl2−/− mice lost more body weight 
than their WT littermates (Figure 5B). Strikingly, we noticed that 
Fgl2−/− mice had more tumors and a higher tumor load than WT 
mice (Figures 5C–E). Collectively, these results suggest that Fgl2 
deficiency promotes CAC development.
DiscUssiOn
Fibrinogen-like protein 2, a pivotal immune regulator, has 
been implicated in the pathogenesis of several inflammatory 
disorders (11, 14). However, the role of Fgl2 in IBD is not well 
understood but may provide valuable insight into IBD patho-
genesis and clues to find novel therapeutic strategies. Here, we 
show that Fgl2 expression is significantly upregulated during 
DSS-induced mouse model of colitis, a widely used model that 
mimics the clinical features of human ulcerative colitis (22). 
This is consistent with recent reports in a 2,4,6-trinitrobenzene 
sulfonic acid-induced mouse model (28) (which resembles 
human CD) (22) and clinical evidence from patients with IBD 
(18). In addition, we demonstrate that Fgl2 exerts a protective 
effect by limiting intestinal inflammation and suppressing CAC. 
In this regard, Fgl2 overexpression in IBD may be the result of 
a feedback mechanism that is important but insufficient in and 
of itself to suppress inflammation. Thus, the use of recombinant 
Fgl2 may be an effective approach to inhibiting intestinal inflam-
mation and tumorigenesis. To this end, the exact mechanisms 
that trigger and maintain Fgl2 expression in colitis should be 
clarified in future.
Fibrinogen-like protein 2 exists in a membrane-bound form 
with pro-coagulant activity and in a secreted form with immune 
regulatory functions (11). Notably, we observed a gradual increase 
in sFgl2 expression with the progression of colitis. Given that 
sFgl2 is readily detected, our results, together with previous find-
ings (18), support the notion that Fgl2, especially sFgl2, may serve 
as a valuable and convenient biomarker for continuous monitor-
ing of IBD progression and response to treatment in both animal 
research and clinical application. In addition to sFgl2, mFgl2 
expression was upregulated in the inflamed colon, implying a role 
for this form in the modulation of intestinal inflammation. In 
terms of structure, mFgl2 and sFgl2 share a common fibrinogen-
related domain that is responsible for the immune-regulatory 
effect of sFgl2. Currently, there is no evidence that mFgl2 acts to 
mount an immunologic response like sFgl2 does. It would be of 
interest to determine whether mFgl2 can limit immunopatho-
logical damage by fibrinogen-related domain-mediated immune 
regulatory activity and if so, its relative contribution in the control 
of intestinal inflammation.
FigUre 5 | Fibrinogen-like protein 2 (Fgl2) deficiency promotes colitis-associated colorectal cancer (CAC). Fgl2−/− mice (n = 7) and WT littermates (n = 8) were 
injected with azoxymethane (AOM) (10 mg/kg); 7 days later, mice were treated with three cycles of dextran sodium sulfate (DSS) (5 days of 1.8% DSS in water and 
16 days of normal water). (a) Induction procedure for AOM/DSS-induced CAC in WT and Fgl2−/− mice. (B) Body weight was monitored throughout the treatment 
regimen (n = 7–8 for WT, n = 6–7 for Fgl2−/−). (c) Representative images of colorectal tumors (n = 7 for WT, n = 6 for Fgl2−/−). (D) Number and size distributions of 
colorectal polyps (n = 7 for WT, n = 6 for Fgl2−/−). (e) Average tumor burden (n = 7 for WT, n = 6 for Fgl2−/−). Data are representative of three independent 
experiments. The statistical significance of differences was determined by two-way analysis of variance (B) with Bonferroni correction and unpaired two-tailed 
Student’s t-test (D,e). *P < 0.05, **P < 0.01.
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Fibrinogen-like protein 2 has been found to be expressed 
in intestinal endothelial cells and infiltrating inflammatory 
cells in mucosal biopsy specimens of patients with IBD (18). 
Intriguingly, Fgl2 was mostly absent in colonic endothelial cells 
in our study. Possible reasons for these seemingly inconsistent 
results are that Fgl2 is expressed by endothelial cells during a 
chronic process that could not be detected in the DSS-induced 
acute colitis model, or that Fgl2 expression profiles differ 
between humans and rodents. We also demonstrated that Fgl2 
is expressed by various inflammatory cell types. Furthermore, 
we proved that Fgl2 function in colitis is related to its expres-
sion in BM-derived cells. To date, experimental evidence is 
still lacking to address which cell type drives Fgl2 expression 
in intestinal inflammation, we found that colonic macrophages 
are the major source of both mFgl2 and sFgl2 in colitis. A recent 
report implied that Tregs and effector T cells control intestinal 
homeostasis through expression of Fgl2 in a T cell-induced coli-
tis model (29). Similarly, we propose here that in the context of 
inflammation, colonic macrophages may through express Fgl2 
partially restore intestinal homeostasis.
Mechanically, we paid special attention to macrophages, 
because they are among the most numerous leukocytes in the 
colon and are key mediators of the initiation and resolution of 
intestinal inflammation by being activated into either the M1 or 
the M2 phenotype (30, 31). In a mouse model of colitis and in 
patients with IBD, M1 macrophages were shown to infiltrate the 
cLP, shifting the balance in the macrophage pool toward a pro-
inflammatory population and undermining epithelial integrity 
via the secretion of corresponding cytokines, ultimately leading 
to intestinal inflammation in IBD (32, 33). We also observed a 
constant pool of M1 macrophages within the lamina propria 
of inflamed gut tissue that was unexpectedly increased by loss 
of Fgl2, with concomitant aggravation of colitis. On the other 
hand, M2 macrophages are enriched in IBD animal models and 
clinical specimens, and this enrichment is inversely correlated 
with disease severity (10, 30, 32). It was previously shown that 
Fgl2 can increase the percentage of M2 macrophages in the 
tumor microenvironment (34). Interestingly, during the late 
stage of DSS-induced acute colitis, colonic M2 accumulation 
was decreased in the absence of Fgl2. Moreover, Fgl2-deficient 
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macrophages exhibited an enhanced M1 response and impaired 
M2 phenotype. Thus, at the early stage of DSS-induced colitis, 
increased M1 polarization and activation by Fgl2 depletion 
may contribute to the exacerbated colitis, whereas during the 
late phase of DSS colitis, suppression of M2 polarization may 
be additionally responsible for colitis aggravation. However, we 
cannot rule out the possibility that Fgl2 deficiency also affects the 
number or activity of other leukocytes, such as Tregs and effector 
T cells, as reported by others (11).
We showed that Fgl2 directly regulates macrophage polari-
zation and function in a cell-intrinsic manner, as loss of Fgl2 
increased the expression of M1-associated genes and cytokines 
in LPS-stimulated PEMs, while reducing that of M2-associated 
genes and cytokines in PEMs activated by IL-4. Macrophage 
polarization is important for the initiation and progression of 
various pathological conditions, including infection, inflam-
mation, atherosclerosis, obesity, asthma, sepsis, and tumors 
(35). Our findings therefore indicate that Fgl2 may act as a 
potential therapeutic target for these diseases owing to its role 
in regulating macrophage polarization. A network of signaling 
molecules, transcription factors, epigenetic mechanisms, and 
post-transcriptional regulators orchestrate macrophage polariza-
tion (36, 37); our results provide evidence that Fgl2 also performs 
this function, although additional studies are needed to clarify 
the precise molecular mechanisms.
In summary, our results presented herein point to Fgl2 as 
a novel protective molecule in the pathogenesis of IBD. We 
found that Fgl2 is critical for limiting DSS-induced colitis and 
subsequent CAC development through its effects on macrophage 
polarization and might serve as a biomarker and/or therapeu-
tic target in the treatment of IBD and other inflammatory 
diseases.
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